Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer

被引：65

作者：

Pu, Dan ^{[1
]}

Yin, Liyuan ^{[1
]}

Huang, Lin ^{[1
]}

Qin, Changlong ^{[1
]}

Zhou, Yuwen ^{[2
]}

Wu, Qiang ^{[1
]}

Li, Yan ^{[1
]}

Zhou, Qinghua ^{[1
]}

Li, Lu ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, Dept Lung Canc Ctr, Lung Canc Ctr, Chengdu, Peoples R China

[2] Sichuan Univ, West China Hosp, Dept Oncol, Chengdu, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

关键词：

cyclooxygenase-2; immunotherapy; cancer; combination therapy; celecoxib; CELL LUNG-CANCER; PHASE-II TRIAL; PD-L1; EXPRESSION; PROGNOSTIC VALUE; CELECOXIB; COX-2; BIOMARKER; BLOCKADE; DRIVEN;

D O I：

10.3389/fonc.2021.637504

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis. It is the key enzyme of prostaglandin E-2 (PGE2) that has been proved to promote the development, proliferation and metastasis of tumor cells. Recent studies further find the PGE2 in tumor microenvironment (TME) actively triggers tumor immune evasion via many ways, leading to poor response of immunotherapy. COX-2 inhibitor is suggested to restrain the immunosuppression of PGE2 and may enhance or reverse the response of immune checkpoint inhibitors (ICIs). This review provides insight into the mechanism of COX-2/PGE2 signal in immunosuppressive TME and summarizes the clinical application and trials in cancer treatment.

引用

页数：7

共 50 条

[1] Cyclooxygenase-2 inhibitor: a potential therapeutic strategy for ultrafiltration failure in peritoneal dialysis
Kim, Yong-Lim
Park, Sun-Hee
Choi, Ji-Young
Kim, Chan-Duck
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (12) : 3585 - 3588
[2] Cyclooxygenase-2 inhibitor and cisplatin combination as a radiosensitizer in the treatment of head and neck cancer patients
Altundag, O
Altundag, K
Morandi, P
Gunduz, M
ANNALS OF ONCOLOGY, 2004, 15 (09) : 1444 - 1445
[3] Combination of exemestane with a cyclooxygenase-2 inhibitor in metastatic breast cancer: results of efficacy and tolerability
Lara, Ricardo
Lastra, Rodrigo
Ortega, Eugenia
Lambea, Julio
Polo, Eduardo
Mayordomo, Jose Ignacio
Tres, Alejandro
Blesa, Lozano
ANNALS OF ONCOLOGY, 2004, 15 : 36 - 36
[4] Doxycycline inhibits cell proliferation and invasive potential: Combination therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells
Onoda, T
Ono, T
Dhar, DK
Yamanoi, A
Fujii, T
Nagasue, N
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2004, 143 (04): : 207 - 216
[5] Cyclooxygenase-2: potential biomarker for cancer prevention
不详
BIOMARKERS IN MEDICINE, 2007, 1 (04) : 485 - 485
[6] Cyclooxygenase-2: A potential target in breast cancer
Wang, DZ
DuBois, RN
SEMINARS IN ONCOLOGY, 2004, 31 (01) : 64 - 73
[7] Chemoprevention of gastric cancer by cyclooxygenase-2 inhibitor in rats
Hu, PJ
Yu, J
Zeng, ZR
Leung, WK
Sung, J
GASTROENTEROLOGY, 2003, 124 (04) : A293 - A293
[8] Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention
Kismet, K
Akay, MT
Abbasoglu, O
Ercan, A
CANCER DETECTION AND PREVENTION, 2004, 28 (02): : 127 - 142
[9] Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells
Song, XQ
Lin, HP
Johnson, AJ
Tseng, PH
Yang, YT
Kulp, SK
Chen, CS
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (08) : 585 - 591
[10] Is cyclooxygenase-2 a player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells?
Johnson, AJ
Song, XQ
Lin, HP
Chen, CS
FASEB JOURNAL, 2002, 16 (04): : A178 - A178

← 1 2 3 4 5 →